Abstract:Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Background BEV is associated with an increased risk of ATE, however, its effect on VTE remains controversial. We investigated the association of BEV treatment and clinical risk factors with the incidence of ATE and VTE in a large randomized phase III study. Methods mCRPC patients were randomized to receive docetaxel and prednisone with or without BEV once every 21 days. Competing risks cycle-to-event Cox regression models were used to investigate the association of BEV on the incidence of grade 3 or higher (3+) ATE (“cardiac ischemia/infarction” or “CNS ischemia”) and VTE (“thrombosis/thrombus/embolism”). Age, prior ATE/VTE, baseline antiplatelet/anticoagulant and VTE risk score were evaluated in univariable and multivariable analyses. Results The analysis included 800 patients. The odds of experiencing grade 3+ ATE was significantly greater in BEV treated patients compared to placebo (OR 4.16, P=0.006; 4.02% [16/398] and 1.00% [4/402], respectively). The odds of experiencing grade 3+ VTE was lower in BEV treated patients compared to placebo (OR=0.57, P=0.08; 4.52% [18/398] and 7.71% [31/402], respectively). In the multivariable analysis, BEV treatment (HR=4.28; P=0.009) and prior ATE (HR=2.71; P=0.047) were associated with increased ATE, while age (HR=1.05; P=0.009) and VTE risk score (HR=2.24; P=0.007), but not BEV treatment (HR=0.62; P=0.11), were associated with increased VTE (Table 1). Conclusion Due to the lack of survival benefit noted in the clinical trial, these results further reinforce the recommendation for not using BEV in this patient population, as it also placed patients at a significantly greater risk for ATE. However, the influence on VTE, if any, was a decreased risk. Understanding the risk factors for ATE and VTE is essential to mitigate risks and reduce the burden of these prevalent complications in cancer care. Table 1 Risk of ATE and VTE by treatment arm and clinical risk factors View this table: Table 1 Risk of ATE and VTE by treatment arm and clinical risk factors Citation Format: Jai N. Patel, Chen Jiang, Daniel L. Hertz, Flora A. Mulkey, Paula N. Friedman, Susan Halabi, Mark J. Ratain, Michael J. Morris, Eric J. Small, Kouros Owzar, William K. Kelly, Howard L. McLeod. Bevacizumab (BEV) and risk of arterial (ATE) and venous thromboembolism (VTE) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401(ALLIANCE). [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3841. doi:10.1158/1538-7445.AM2014-3841

Risk factors for bevacizumab-related proteinuria in patients with colorectal cancer and non-small cell lung cancer

Bevacizumab Significantly Increases the Risks of Hypertension and Proteinuria in Cancer Patients: A Systematic Review and Comprehensive Meta-Analysis

Efficacy and Toxicity of Addition of Bevacizumab to Chemotherapy in Patients with Metastatic Colorectal Cancer.

Risk and Incidence of Infection with Bevacizumab in Non-Small-Cell Lung Cancer Patients: A Meta-Analysis

Evaluation of proteinuria monitoring practice patterns and treatment implications in patients with cancer receiving bevacizumab products

A Prospective, Multicenter, Observational Study of Bevacizumab in Combined with Chemotherapy As First-Line or Second-Line Treatment in Chinese Metastatic Colorectal Cancer

The Optimal Timing And Courses Of Bevacizumab Added To Chemotherapy For Non-Squamous Non-Small Cell Lung Cancer: Revelations From The Real-World Experience In A Single Chinese Cancer Center

Clinical Study on the Safety of Bevacizumab in the Treatment of Patients with Advanced Colorectal Cancer

Risks of hypertension and thromboembolism in patients receiving bevacizumab with chemotherapy for colorectal cancer: A systematic review and meta‐analysis

Efficacy and safety of bevacizumab (BEV)plus chemotherapeutic agents in the treatment of metastatic colorectal cancer (mCRC)

Total and Not Bevacizumab-Bound Vascular Endothelial Growth Factor As Potential Predictive Factors to Bevacizumab-Based Chemotherapy in Colorectal Cancer.

A Prospective Multicenter Observational Study of Bevacizumab for the Treatment of Metastatic Colorectal Cancer in Chinese Patients (obtain Study).

Bevacizumab in combination with various chemotherapy protocols for treatment of advanced colorectal cancer:a clinical evaluation

Increased incidence of chemoport-related thrombosis in patients with colorectal cancer receiving bevacizumab: A single-institutional experience

A Retrospective Exploration of Targeted Maintenance Therapy in Advanced Colorectal Cancer: Based on the Background of Chinese Patient Assistance Program.

Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients

Bevacizumab and the Risk of Arterial and Venous Thromboembolism in Patients with Metastatic, Castration-Resistant Prostate Cancer Treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).

Bevacizumab (Bev) And Risk Of Arterial (Ate) And Venous Thromboembolism (Vte) In Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients Treated On Calgb 90401(Alliance)

Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumab and Chemotherapy: Results from the BRiTE Observational Cohort Study

Efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer according to programmed cell death ligand 1

Effectiveness and Safety of Adding Bevacizumab to Platinum-Based Chemotherapy as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis